SPOTLIGHT: Lilly settles 900 more Zyprexa claims

Eli Lilly has settled some 900 lawsuits over its antipsychotic drug Zyprexa, including five set to go to trial next month, leaving about 1,100 claims unsettled. Many of the plaintiffs alleged that Lilly downplayed the drug's side effects, including weight gain and elevated blood sugar. The company has set aside $1.2 billion to cover the claims. Report | Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.